Atl146e

DB05191InvestigationalSmall molecule

ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

Mechanism: ATL146e can inhibit neutrophil, macrophage and T cell activation and thereby reduce inflammation caused autoimmune responses. It also inhibits TNF-α and IL-1/3 production, neutrophil accumulation in gastric injury induced by NSAIDS (such as aspirin) without affecting mucosal prostaglandin E2 (PGE2) concentration. The effects of adenosine A2A agonists can be enhanced by type IV phosphodiesterase inhibitors, such as rolipram.
Curator reviewed
Primary indication: Investigated for use/treatment in inflammatory disorders (unspecified).Curator reviewed
Code names: Atl146e

Resolves to

Targets

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atl146e, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.